Natalie D DiProspero1,2, David B Keator3, Michael Phelan4, Theo G M van Erp5, Eric Doran5, David K Powell6, Kathryn L Van Pelt7, Frederick A Schmitt7,8, Elizabeth Head9, Ira T Lott5, Michael A Yassa1,2,3. 1. Department of Neurobiology and Behavior, University of California, Irvine, CA, USA. 2. Center for the Neurobiology of Learning and Memory, University of California, Irvine, CA, USA. 3. Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA. 4. Institute for Memory Impairments and Neurological Disorders, UC Irvine, CA, USA. 5. Department of Pediatrics, University of California, Irvine Medical Center, Orange, CA, USA. 6. Department of Neuroscience, University of Kentucky Medical Center, Lexington, KY, USA. 7. Sanders-Brown Center on Aging, University of Kentucky Medical Center, Lexington, KY, USA. 8. Department of Neurology, University of Kentucky Medical Center, Lexington, KY, USA. 9. Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA.
Abstract
BACKGROUND: Down syndrome (DS) is associated with increased risk for Alzheimer's disease (AD). In neurotypical individuals, clinical AD is preceded by reduced resting state functional connectivity in the default mode network (DMN), but it is unknown whether changes in DMN connectivity predict clinical onset of AD in DS. OBJECTIVE: Does lower DMN functional connectivity predict clinical onset of AD and cognitive decline in people with DS? METHODS: Resting state functional MRI (rsfMRI), longitudinal neuropsychological, and clinical assessment data were collected on 15 nondemented people with DS (mean age = 51.66 years, SD = 5.34 years, range = 42-59 years) over four years, during which 4 transitioned to dementia. Amyloid-β (Aβ) PET data were acquired on 13 of the 15 participants. Resting state fMRI, neuropsychological, and clinical assessment data were also acquired on an independent, slightly younger unimpaired sample of 14 nondemented people with DS (mean age = 44.63 years, SD = 7.99 years, range = 38-61 years). RESULTS: Lower functional connectivity between long-range but not short-range DMN regions predicts AD diagnosis and cognitive decline in people with DS. Aβ accumulation in the inferior parietal cortex is associated with lower regional DMN functional connectivity. CONCLUSION: Reduction of long-range DMN connectivity is a potential biomarker for AD in people with DS that precedes and predicts clinical conversion.
BACKGROUND: Down syndrome (DS) is associated with increased risk for Alzheimer's disease (AD). In neurotypical individuals, clinical AD is preceded by reduced resting state functional connectivity in the default mode network (DMN), but it is unknown whether changes in DMN connectivity predict clinical onset of AD in DS. OBJECTIVE: Does lower DMN functional connectivity predict clinical onset of AD and cognitive decline in people with DS? METHODS: Resting state functional MRI (rsfMRI), longitudinal neuropsychological, and clinical assessment data were collected on 15 nondemented people with DS (mean age = 51.66 years, SD = 5.34 years, range = 42-59 years) over four years, during which 4 transitioned to dementia. Amyloid-β (Aβ) PET data were acquired on 13 of the 15 participants. Resting state fMRI, neuropsychological, and clinical assessment data were also acquired on an independent, slightly younger unimpaired sample of 14 nondemented people with DS (mean age = 44.63 years, SD = 7.99 years, range = 38-61 years). RESULTS: Lower functional connectivity between long-range but not short-range DMN regions predicts AD diagnosis and cognitive decline in people with DS. Aβ accumulation in the inferior parietal cortex is associated with lower regional DMN functional connectivity. CONCLUSION: Reduction of long-range DMN connectivity is a potential biomarker for AD in people with DS that precedes and predicts clinical conversion.
Entities:
Keywords:
Alzheimer’s disease; Down syndrome; biomarkers; default mode network; dementia; functional connectivity; resting state functional magnetic resonance imaging
Authors: Jonathan D Power; Anish Mitra; Timothy O Laumann; Abraham Z Snyder; Bradley L Schlaggar; Steven E Petersen Journal: Neuroimage Date: 2013-08-29 Impact factor: 6.556
Authors: Marwan N Sabbagh; Kewei Chen; Joseph Rogers; Adam S Fleisher; Carolyn Liebsack; Dan Bandy; Christine Belden; Hillary Protas; Pradeep Thiyyagura; Xiaofen Liu; Auttawut Roontiva; Ji Luo; Sandra Jacobson; Michael Malek-Ahmadi; Jessica Powell; Eric M Reiman Journal: Alzheimers Dement Date: 2015-04-04 Impact factor: 21.566
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Brian B Avants; Nicholas J Tustison; Gang Song; Philip A Cook; Arno Klein; James C Gee Journal: Neuroimage Date: 2010-09-17 Impact factor: 6.556
Authors: Douglas N Greve; Claus Svarer; Patrick M Fisher; Ling Feng; Adam E Hansen; William Baare; Bruce Rosen; Bruce Fischl; Gitte M Knudsen Journal: Neuroimage Date: 2013-12-19 Impact factor: 6.556
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566